Related Experiment Video

Updated: Mar 13, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.3K

Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy

Lai Yue Chan1, David J Craik1, Norelle L Daly2

  • 1The University of Queensland, Institute for Molecular Bioscience, 4072 Brisbane, Australia.

Scientific Reports
|October 14, 2016
PubMed

Insights

Researchers developed a novel, non-toxic cyclic peptide by combining two anti-angiogenic epitopes. This 2-in-1 peptide shows potent inhibition of cancer angiogenesis, offering a promising new combination therapy approach.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Bioactive hormone peptide analogues show promise as angiogenesis inhibitors for cancer.
  • Current anti-angiogenesis therapies face challenges like drug resistance, toxicity, and side effects.
  • Combination therapy is used to target multiple cancer signaling pathways, but often involves cytotoxic drugs.

Purpose of the Study:

  • To develop a novel, non-toxic cyclic peptide by combining two distinct anti-angiogenic epitopes into a single molecule.
  • To assess the anti-angiogenic activity and potency of this novel peptide analogue.
  • To investigate the potential of this 2-in-1 peptide as a combination therapy for cancer.

Main Methods:

  • Two anti-angiogenic epitopes acting on different pathways were combined into a cyclic peptide framework, MCoTI-II (Momordica cochinchinensis trypsin inhibitor-II).
  • The anti-angiogenic activity was evaluated using in vitro endothelial cell migration assays.
  • In vivo efficacy was assessed using the chorioallantoic membrane angiogenesis assay.

Main Results:

  • A potent, non-toxic, and stable cyclic peptide analogue was successfully developed.
  • The novel peptide demonstrated nanomolar potency in inhibiting endothelial cell migration.
  • Significant inhibition of angiogenesis was observed in the in vivo chorioallantoic membrane assay.

Conclusions:

  • The combination of two anti-angiogenic epitopes within the MCoTI-II framework resulted in a synergistic effect, enhancing anti-angiogenic potency.
  • This 2-in-1 peptide represents a novel approach to combination therapy, potentially overcoming limitations of current cancer treatments.
  • The developed peptide analogue shows promise for targeting a wide range of cancers with improved efficacy and reduced toxicity.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K